Influence of comorbidity of cerebrovascular disease and amyloid-β on Alzheimer’s disease
Alzheimer’s Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-beta Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study
Be part of something life-changing
The AIBL study uses biomarkers in the body to identify Alzheimer’s disease risks in a person. Participating in this research may help you detect early brain changes and identify your risk of developing Alzheimer's disease. The ongoing success of our research relies on the generosity of volunteers. Your involvement helps researchers develop earlier detection methods and treatments.
Find out if you’re eligible
If you are over 65 and worried about your memory or have a diagnosed memory problem, you may be eligible to participate in our study.
If you live in Melbourne or Perth and would like more information about participating in this study, please contact your local AIBL representative.
You can also register your interest through the Australian Dementia Network (ADNet) to participate in clinical trials for promising Alzheimer’s disease therapies.
News and events
Get the latest global news about dementia research.
Explore innovations and clinical developments in Alzheimer’s disease.
External resources for participants